newsfilter
← Latest News
GlobeNewswire·

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 - - Strong balance